This paper is in the following e-collection/theme issue:

Physician and Health Services Rating by Consumers (126) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (146) Pharmacovigilance (128) Insomnia and Sleep Hygiene (151)

Published on in Vol 21, No 11 (2019): November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/13371, first published .
Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study

Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study

Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study

Authors of this article:

Jill S Borchert1 Author Orcid Image ;   Bo Wang2 Author Orcid Image ;   Muzaina Ramzanali1 Author Orcid Image ;   Amy B Stein3 Author Orcid Image ;   Latha M Malaiyandi4 Author Orcid Image ;   Kirk E Dineley4 Author Orcid Image
Article Authors Cited by (13) Tweetations (4) Metrics

Journals

  1. Peng W, Zhao Y, Wang Y, Wang J, Hao Q, Tu Y, Zhu T. Comparison between acupuncture and cognitive behavioral therapy for primary insomnia. Medicine 2020;99(21):e20453 View
  2. Siclari F, Valli K, Arnulf I. Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders. The Lancet Neurology 2020;19(10):849 View
  3. Langade D, Thakare V, Kanchi S, Kelgane S. Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study. Journal of Ethnopharmacology 2021;264:113276 View
  4. Trajanović N. Dual orexin receptor antagonist in treatment of insomnia. Engrami 2020;42(2):57 View
  5. Feipeng G, Luxin X, Beili C, Songhong Y, Wenting W, Junmao L, Qianfeng G, Lingyun Z, Jianxiong W, Huang J. Exploration of Ziziphi Spinosae Semen in Treating Insomnia Based on Network Pharmacology Strategy. Evidence-Based Complementary and Alternative Medicine 2021;2021:1 View
  6. Gordijn R, Wessels W, Kriek E, Nicolai M, Elzevier H, Visser L, Guchelaar H, Teichert M. Patient reporting of sexual adverse events on an online platform for medication experiences. British Journal of Clinical Pharmacology 2022;88(12):5326 View
  7. Yoshioka R, Yamamoto S, Nakatani E, Yasui-Furukori N. Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study. PLOS ONE 2023;18(4):e0284726 View
  8. Del Rio Verduzco A, Salari A, Haghparast P. Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports. Mental Health Clinician 2023;13(5):244 View
  9. Freund W, Weber F. The function of sleep and the treatment of primary insomnia. Deutsches Ärzteblatt international 2023 View
  10. Costantino R, Gressler L, Zarzabal L, Vasquez C, Juneau R. Medication Trends in the Military: A Comparative Analysis of Prescribing Patterns Among Service Members Seen by a Pharmacist and Implications for Medical Readiness. Military Medicine 2024;189(7-8):e1577 View
  11. Grigg-Damberger M. Is there a better way to wean chronic benzodiazepine receptor agonists use by substituting a DORA (and starting CBT-I)?Commentary on Tachibana M, Kanahara N, Oda Y, Hasegawa T, Kimura A, Iyo M. A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists. J Clin Sleep Med . 2024;20(4):603–613. doi:10.5664/jcsm.10946. Journal of Clinical Sleep Medicine 2024;20(4):483 View
  12. Golder S, O'Connor K, Wang Y, Klein A, Gonzalez Hernandez G. The value of social media analysis for adverse events detection and pharmacovigilance: a Scoping Review (Preprint). JMIR Public Health and Surveillance 2024 View

Books/Policy Documents

  1. Haghparast P, Pondrom M, Ray S. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. View